A four‐miRNA signature identified from genome‐wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma

Abstract

Recent findings have reported that human serum microRNAs (miRNAs) can be used as prognostic biomarkers in various cancers. We aimed to explore the prognostic value of serum miRNAs in nasopharyngeal carcinoma (NPC) patients. The level of serum miRNA was retrospectively analyzed in 512 NPC patients recruited between January 2001 and December 2006. In the discovery stage, a microarray followed by reverse transcription-quantitative polymerase chain reaction was used to identify differentially altered miRNAs in eight patients with shorter survival and eight patients with longer survival who were well matched by age, sex and clinical stage. The identified serum miRNAs were then validated in all 512 samples, which were randomly divided into a training set and a validation set. Four serum miRNAs (miR-22, miR-572, miR-638 and miR-1234) were found to be differentially altered and were used to construct a miRNA signature. Risk scores were calculated to classify the patients into high-or low-risk groups. Patients with high-risk scores had poorer overall survival [hazard ratio (HR), 2.54; 95% confidence interval (CI), 1.57-4.12; p < 0.001] and distant metastasis-free survival (HR, 3.28; 95% CI, 1.82-5.94; p < 0.001) than those with low-risk scores in the training set; these results were confirmed in the validation and combined sets. The miRNA signature and TNM stage were independent prognostic factors. The combination of the miRNA signature and TNM stage had a better prognostic value than the TNM stage or miRNA signature alone. The four-serum miRNA signature may add prognostic value to the TNM staging system and provide information for personalized therapy in NPC.According to the International Agency for Research on Cancer, there were an estimated 84,400 incident cases of nasopharyngeal carcinoma (NPC) and 51,600 deaths in 2008.

Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer

“…It inhibits cell cycle progression by repressing Max and ErbB3 expression post-transcriptionally, mediates the effects of the tumor-suppressor p53, and suppresses interferon gene expression by blocking interferon regulatory factor-5 [49][50][51] . MiR-22 has been proposed as a potential serum marker for non-small cell lung cancer [52] , esophageal squamous cell carcinoma [53] , and nasopharyngeal carcinoma [54] . Our experimental strategy in this study focused on using hybridization-based microarray technology as the means to screen thousands of genes simultaneously, but it is also severely limited due to its issues with reproducibility and its tendency to produce a high rate of false positive and false negative results.…”

Five miRNAs as Novel Diagnostic Biomarker Candidates for Primary Nasopharyngeal Carcinoma

“…Conversely, the down-regulation of tumor suppressor gene expression by microRNAs (miRNAs) is increasingly recognized to be an important mechanism of nasopharyngeal tumorigenesis (Li et al, 2014;Ma et al, 2014). miRNAs are endogenous, small non-coding RNA molecules that completely or partially bind to target mRNAs and either block translation or lead to degradation to ultimately inhibit gene expression (Li et al, 2011;Marquitz et al, 2012;Liu et al, 2014). miRNAs serve as essential posttranscriptional regulators that can specifically influence cancer development and progression, with aberrant expression patterns observed in multiple cancer types (Marquitz, 2012).…”

Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance

“…Furthermore, miR-638 was identified as a potential predictor of early virological response to interferon treatment in patients with chronic hepatitis B (15). In addition, miR-638 was one of the four miRNAs identified through genome-wide serum miRNA profiling that predict the survival rate of patients with nasopharyngeal carcinoma (28). A previous study demonstrated that the downregulation of miR-638 in colorectal cancer predicts poor survival (13).…”